Firebrick Pharma (ASX:FRE) announced that the Philippines has accepted its patent for the use of povidone-iodine in preventing and treating highly pathogenic viruses, including SARS-CoV-2.
The patent, titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes," provides commercial protection until 2040 for the company’s Nasodine nasal spray and related PVP-I preparations.
Beyond nasal applications, the granted claims cover the use of gargles and throat sprays to reduce viral load and shedding.
While the patent strengthens Firebrick's position in a key international market, the company is currently seeking regulatory approval to commence sales in the Philippines, with a target date set for later in 2026.